Add this topic to your myFT Digest for news straight to your inbox
Felix Ehrat to ‘take personal responsibility’ for agreement with Michael Cohen
Federal and local authorities ‘in contact’ over possible concern at payments
Move to shed consumer health unit by Swiss group’s new CEO aims at focusing business
Drugmakers say trackable medicine will add value and benefit patients and payers
Drugmaker to focus on turnround at eyecare unit before making final decision
Swiss group’s head of drug development Vas Narasimhan succeeds long-serving boss
Drugmaker is exploring whether to spin out Alcon division
Start-ups are developing gadgets that are reducing the need for medication
Industry executives welcome president’s vow as way to lower prices
Swiss drugmaker weighs options for underperforming eyecare unit
Swiss pharmaceuticals group warns of tougher environment ‘no matter which candidate wins’
Joe Jimenez eyes ageing demographics and growing middle class despite increasing challenges
Sales and profits are expected to be down as the eyecare business continues to drag on performance
Drugmaker seeks $1bn annual savings and sets deadline to turnround division after sales dip
Drugmaker reports quarterly net income of $1.8bn, down 42% due to charge
Move to seize opportunity in convergence of healthcare and digital communications as populations age
Industry recovers from the innovation drought that depressed growth in past decade
Swiss pharmaceutical group suffers from strong dollar and weakness in Alcon division
New model must be based on patient outcomes if Europe’s health systems are to remain solvent
Earnings hurt by strong dollar but underlying profits helped by better productivity
Drugmakers unsettled as large tech groups turn to healthcare
International Edition